About: Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque
Creator	Zheng, Bo-Jian Xu, Jun Qin, Chuan Zhong, Nanshan Wei, Qiang Xie, Frank Lu, Y Woodle, Martin Cheng, Du Liu, Yijia Tang, Qingquan Li, Bao-Jian Patrick, &
Source	Medline; PMC
abstract	Development of therapeutic agents for severe acute respiratory syndrome (SARS) viral infection using short interfering RNA (siRNA) inhibitors exemplifies a powerful new means to combat emerging infectious diseases. Potent siRNA inhibitors of SARS coronavirus (SCV) in vitro were further evaluated for efficacy and safety in a rhesus macaque (Macaca mulatta) SARS model using clinically viable delivery while comparing three dosing regimens. Observations of SARS-like symptoms, measurements of SCV RNA presence and lung histopathology and immunohistochemistry consistently showed siRNA-mediated anti-SARS efficacy by either prophylactic or therapeutic regimens. The siRNAs used provided relief from SCV infection–induced fever, diminished SCV viral levels and reduced acute diffuse alveoli damage. The 10–40 mg/kg accumulated dosages of siRNA did not show any sign of siRNA-induced toxicity. These results suggest that a clinical investigation is warranted and illustrate the prospects for siRNA to enable a massive reduction in development time for new targeted therapeutic agents. SUPPLEMENTARY INFORMATION: The online version of this article (doi:10.1038/nm1280) contains supplementary material, which is available to authorized users.
has issue date	2005-08-21(xsd:dateTime)
bibo:doi	10.1038/nm1280
bibo:pmid	16116432
has license	no-cc
sha1sum (hex)	76ed0c3743e565a6a45e47040fd7e8ea0b1f5b97
schema:url	https://doi.org/10.1038/nm1280
resource representing a document's title	Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque
has PubMed Central identifier	PMC7095788
has PubMed identifier	16116432
schema:publication	Nat Med
resource representing a document's body	covid:76ed0c3743e565a6a45e47040fd7e8ea0b1f5b97#body_text
is schema:about of	named entity 'efficacy' named entity 'acute' named entity 'lung' named entity 'sign' named entity 'SCV' named entity 'damage' named entity 'prophylactic' named entity 'SARS' named entity 'INDUCED' named entity 'DOSAGES' named entity 'PROVIDED' named entity 'RNA' named entity 'SHORT INTERFERING RNA' named entity 'DELIVERY' named entity 'RESULTS' named entity 'RHESUS MACAQUE' named entity 'MASSIVE' named entity 'SYMPTOMS' named entity 'FEVER' named entity 'TIME' named entity 'PROPHYLACTIC' named entity 'DIMINISHED' named entity 'COMBAT' named entity 'CLINICAL INVESTIGATION' named entity 'INFECTION' named entity 'PRESENCE' named entity 'RELIEF' named entity 'REGIMENS' named entity 'REDUCTION' named entity 'IN VITRO' named entity 'SIGN OF' named entity 'THESE' named entity 'SIRNA' named entity 'SARS CORONAVIRUS' named entity 'REDUCED' named entity 'SUGGEST' named entity 'EFFICACY' named entity 'THERAPEUTIC AGENTS' named entity 'DID' named entity 'LUNG' named entity 'SAFETY' named entity 'NEW' named entity 'SARS CORONAVIRUS' named entity 'VIABLE' named entity 'IMMUNOHISTOCHEMISTRY' named entity 'INHIBITORS' named entity 'RHESUS MACAQUE' named entity 'VIRAL INFECTION' named entity 'USED' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME' named entity 'R T' named entity 'PROPHYLACTIC' named entity 'REGIMENS' named entity 'ACCUMULATED' named entity 'MEDIATED' named entity 'THERAPEUTIC' named entity 'MG%' named entity 'TARGETED' named entity 'USING' named entity 'SIRNA' named entity 'SIRNAS' named entity 'THERAPEUTIC' named entity 'POWERFUL' named entity 'EMERGING INFECTIOUS DISEASES' named entity 'TOXICITY' named entity 'HISTOPATHOLOGY' named entity 'ENABLE' named entity 'DAMAGE' named entity 'COMPARING'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software